Conditionally active biologics (CAB) technology
Chimeric Antigen Receptor (CAR)-T cell therapy has delivered remarkable on-target responses to certain hematological malignancies. However, in solid tumors, on-target, off-tumor toxicity has limited the number of antigens available for potent targeting by CAR-T technology. CAB technology takes advantage of the unique microenvironment associated with different diseases and tissues, such as solid tumors, which can result from differences in metabolism between diseased and normal tissue. CAB-CAR-Ts, therefore, will specifically target the tumor microenvironment, as opposed to normal tissue, thereby reducing potential on-target, off-tumor toxicity. Click here to read more.
Economically viable and accessible CAR-T therapies
One of the major challenges facing CAR-T therapies is the potential cost to both the insurer and the patient. At F1, developing solutions that are efficacious and accessible is one of our core values, and we are working on methods to bring down the cost of these therapies and deliver truly point-of-care treatments.